Research programme: bispecific autoimmune disorder therapeutics - Cue biopharma
Alternative Names: CUE-400 series; CUE-500 seriesLatest Information Update: 01 Apr 2021
At a glance
- Originator Cue Biopharma
- Class Recombinant fusion proteins
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Graft-versus-host disease; Transplant rejection
Most Recent Events
- 17 Mar 2021 Bispecific autoimmune disorder therapeutics - Cue biopharma is available for licensing as of 17 Mar 2021. https://www.cuebiopharma.com/partnering/
- 17 Mar 2021 Early research in Transplant rejection in USA (unspecified route) (Cue Biopharma website, March 2021)
- 15 Mar 2021 Early research in Autoimmune disorders in USA (unspecified route) (Cue Biopharma website, March 2021)